Plus   Neg

AnaptysBio Inc. (ANAB) Soared To A New High On Phase 2 Study Results

AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a trial of ANB020 Tuesday morning. An Eczema Area Severity Index score improvement of 50 percent relative to enrollment baseline was observed in 75 percent of patients after a single dose.

AnaptysBio gapped open sharply higher Tuesday and rose steadily throughout the first half of the session. The stock took out the highs of the day going into the close and finished up by 35.41 at $70.41 on the highest volume of the year. AnaptysBio soared to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT